


Ask a doctor about a prescription for Noclaud
Cilostazol
Noclaud contains the active ingredient cilostazol and belongs to a group of medicines called phosphodiesterase type 3 inhibitors. It has various effects, including the dilation of certain blood vessels and the reduction of the activity of blood clotting (aggregation) of certain blood cells, called platelets, within blood vessels.
Noclaud has been prescribed to treat "intermittent claudication". Intermittent claudication is a type of cramp-like pain in the lower limbs that occurs during walking and is caused by insufficient blood flow to the legs. Noclaud increases the distance that the patient can walk without experiencing pain by improving blood circulation in the lower limbs.
Cilostazol is recommended only for patients who have not had sufficient relief from symptoms after lifestyle modifications (including quitting smoking and increasing exercise intensity) and other appropriate interventions. It is essential that the patient continues to follow the lifestyle modifications during cilostazol treatment.
Before starting treatment with Noclaud, the patient should discuss it with their doctor or pharmacist
During treatment with Noclaud
Noclaud is not intended for children.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
In particular, the patient should inform their doctor about taking certain medicines that are usually used to treat pain and/or inflammation of muscles or joints, as well as medicines that reduce blood clotting. These medicines include:
If the patient is taking such medicines with Noclaud, their doctor may perform certain routine blood tests.
Some medicines taken at the same time as Noclaud may interfere with its effects. They may increase the risk of side effects or reduce the effectiveness of Noclaud. Noclaud may also affect other medicines. Before starting treatment with Noclaud, the patient should inform their doctor about taking:
In case of doubt about whether the above applies to the medicines taken by the patient, they should consult their doctor or pharmacist.
Before starting treatment with Noclaud, the patient should inform their doctor if they are taking medicines for high blood pressure, as Noclaud may cause additional blood pressure-lowering effects. If blood pressure drops too low, it may lead to rapid heart rate. These medicines include:
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
Noclaud MUST NOTbe used during pregnancy.
IT IS NOT RECOMMENDEDto use Noclaud in breastfeeding mothers.
Noclaud may cause dizziness. If the patient experiences dizziness after taking Noclaud, they MUST NOTdrive vehicles, use tools, or operate machines. They should inform their doctor or pharmacist.
This medicine should always be taken as directed by the doctor or pharmacist. In case of doubt, the patient should consult their doctor or pharmacist.
Some benefits of using Noclaud may be noticeable after 4-12 weeks of treatment.
The doctor will assess the effectiveness after 3 months of treatment and may recommend stopping cilostazol treatment if the therapy is not effective enough.
Noclaud is not intended for children.
If the patient has taken more tablets of Noclaud than they should, they may experience objective and subjective symptoms, such as severe headaches, diarrhea, low blood pressure, and irregular heart rhythm.
In case of taking a higher dose than prescribed, the patient should immediately contact their doctor or local hospital. They should remember to take the packaging with them so that it is clear what medicine was taken.
There is no reason to worry if a dose is missed. The patient should wait and take the next dose at the right time, and then continue taking the medicine as directed. They MUST NOTtake a double dose to make up for the missed tablet.
If the patient stops using Noclaud, the pain in the lower limbs may return or worsen. Therefore, the patient should only stop using Noclaud if they experience side effects that require urgent medical attention (see section 4) or on the advice of their doctor.
In case of any further doubts about using this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Noclaud can cause side effects, although not everybody gets them.
If the patient experiences any of the following side effects, they may need urgent medical attention. They should stop using Noclaud and contact their doctor or go to the nearest hospital.
The patient should also inform their doctor immediately if they experience fever or sore throat.
It may be necessary to perform certain blood tests, and the doctor will decide on further treatment.
The patient should inform their doctor as soon as possible if they experience any of the following side effects:
Very common side effects(may affect more than 1 in 10 people)
In patients with diabetes, there may be a higher risk of bleeding into the eye.
Rare side effects(may affect up to 1 in 1,000 people)
During treatment with cilostazol, the following side effects have been reported, but their frequency is unknown(cannot be estimated from the available data):
If any of the side effects worsen, the patient should inform their doctor or pharmacist.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, Website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
There are no special precautions for storage.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Do not use this medicine if visible signs of deterioration are observed (e.g., discoloration).
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Appearance:
Odorless or almost odorless, white or almost white, round, flat tablets with beveled edges. The tablets have a stylized letter E and the number 602 embossed on one side, with no markings on the other side.
Packaging:
28 (2 x 14) or 56 (4 x 14) tablets in PVC/PVDC/Al blisters in a cardboard box with a patient information leaflet.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Egis Pharmaceuticals PLC
Keresztúri út 30-38.
1106 Budapest
Hungary
Egis Pharmaceuticals PLC
Bökényföldi út 118-120
1165 Budapest
Hungary
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warsaw
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warsaw
SHIRAZ PRODUCTIONS Sp. z o.o.
ul. Tymiankowa 24/28
95-054 Ksawerów
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in the Czech Republic, the country of export: 83/149/14-C
Hungary
Noclaud 100 mg tablet
Bulgaria
Ноклауд 100 mg таблетки
Czech Republic
Noclaud
Latvia
Sollazon 100 mg tabletes
Lithuania
Sollazon 100 mg tabletės
Poland
Noclaud
Romania
Noclaud 100 mg comprimate
Slovakia
Noclaud 100 mg
Date of approval of the leaflet: 29.06.2022
[Information about the trademark]
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Noclaud – subject to medical assessment and local rules.